Multiple randomized controlled trials have shown that tesamorelin, a growth hormone–releasing hormone analog, can selectively reduce visceral fat by about 15% over 26 weeks in HIV patients, with no ...
(RTTNews) - Theratechnologies Inc. (THTX, TH.TO) announced the availability of EGRIFTA WR (tesamorelin) for injection, approved earlier this year by the U.S. Food and Drug Administration, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results